Description
UroFuraginum Max is a medicinal product that inhibits the growth of many bacterial pathogens responsible for urinary tract infections.
Composition
The active substance is furazidin (also known as furagin).
Other ingredients: lactose monohydrate, silicified microcrystalline cellulose (98% microcrystalline cellulose, 2% colloidal anhydrous silica), magnesium stearate, colloidal anhydrous silica, sodium starch glycolate type A.
Dosage and Administration
This medicine should always be taken exactly as described in the patient information leaflet or as directed by a physician or pharmacist. In case of doubt, consult a healthcare professional.
Adults and adolescents over 15 years of age
-
Day 1: 400 mg daily in 4 divided doses (one tablet every 6 hours).
-
Subsequent days: 300 mg daily in 3 divided doses (one tablet every 8 hours).
The tablet may be divided into equal doses. For oral use. UroFuraginum Max should be taken with meals, together with a high-protein diet. The medicine should be taken with plenty of fluids.
The usual duration of therapy is 7–8 days. If symptoms worsen or do not improve after this period, medical advice should be sought.
Pharmacological Action
UroFuraginum Max contains furazidin (furagin), a nitrofuran derivative. Furazidin inhibits the growth of multiple bacterial strains responsible for urinary tract infections.
Indications
UroFuraginum Max is indicated for the treatment of lower urinary tract infections.
Contraindications
Do not use UroFuraginum Max if:
-
the patient is allergic to furazidin, nitrofuran derivatives, or any excipient of the product;
-
during the first trimester of pregnancy;
-
at term (from week 38 of gestation) or during labour due to the risk of haemolytic anaemia in the newborn;
-
in children and adolescents under 15 years of age;
-
in patients with peripheral polyneuropathy (e.g., diabetic neuropathy);
-
in patients with glucose-6-phosphate dehydrogenase deficiency, due to risk of haemolysis;
-
in renal insufficiency (oliguria, anuria) or when creatinine clearance is below 60 mL/min, or in cases of elevated serum creatinine levels.
Possible Side Effects
Like all medicines, this product may cause adverse reactions, although not everyone will experience them.
The most commonly reported adverse events during clinical studies were:
-
nausea (8%),
-
headache (6%),
-
flatulence (1.5%).
Other reactions occurred in ≤1% of patients.
Stop using the medicine immediately and seek medical attention if any of the following occur:
-
allergic reactions (rash, itching, urticaria, anaphylaxis, angioedema);
-
severe cutaneous adverse reactions: exfoliative dermatitis, erythema multiforme, Stevens–Johnson syndrome;
-
acute, subacute or chronic hypersensitivity reactions to nitrofurans, including pulmonary toxicity (e.g., pulmonary fibrosis, interstitial pneumonitis);
-
pseudomembranous colitis;
-
peripheral neuropathy (tingling, numbness, electric-shock sensations);
-
hepatic dysfunction (hepatitis, cholestatic jaundice, hepatic necrosis).
Other possible adverse effects include:
cyanosis due to methaemoglobinaemia, dizziness, drowsiness, visual disturbances, constipation, diarrhoea, dyspepsia, abdominal pain, vomiting, sialadenitis, pancreatitis, alopecia, fever, chills, malaise, and infections caused by microorganisms resistant to nitrofurans (e.g., Pseudomonas spp., Candida spp.).
Muscle cramps and myalgia have also been reported (frequency unknown).
Warnings and Precautions
Before starting the treatment, consult a physician or pharmacist if the patient has:
-
renal impairment,
-
hepatic impairment,
-
neurological disorders,
-
anaemia,
-
electrolyte imbalance, vitamin B deficiency or folic acid deficiency,
-
pulmonary disease.
Therapy should be discontinued immediately and medical consultation sought if respiratory symptoms, neurological symptoms, or hepatic dysfunction occur.
Long-term treatment may require monitoring of blood count, renal and hepatic function.
Laboratory interactions: the medicine may cause false-positive urine glucose tests. Inform healthcare providers that you are taking UroFuraginum Max prior to testing.
Contains lactose: Each 100 mg tablet contains 123 mg lactose monohydrate. Patients with lactose intolerance should consult a physician before use.
Contains sodium: Less than 1 mmol (23 mg) per tablet—essentially “sodium-free”.
Interaction with Other Medicines
Inform a doctor or pharmacist about all medicines taken currently or recently.
-
Do not combine nitrofuran derivatives with chloramphenicol, ristomycin, sulfonamides, or levomycetin due to risk of bone marrow suppression.
-
Do not use with nalidixic acid or other quinolone derivatives due to antagonistic interaction.
-
Aminoglycosides and tetracyclines may potentiate the antibacterial effect of furazidin.
-
Probenecid (high doses) and sulfinpyrazone may inhibit tubular secretion and increase toxicity.
-
Antacids containing magnesium trisilicate reduce furazidin absorption.
-
Atropine delays absorption, but the total absorbed dose remains unchanged.
-
Vitamin B supplementation increases absorption of nitrofurans.
Pregnancy and Breastfeeding
If the patient is pregnant, breastfeeding, planning pregnancy, or suspects pregnancy, medical advice should be sought before using the medicine.
Use in Children and Adolescents
UroFuraginum Max must not be used in patients under 15 years of age.
Effects on Ability to Drive and Use Machines
No data are available. However, dizziness, drowsiness, and visual disturbances may occur and may impair the ability to drive or operate machinery.
